Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report

Tyrosine kinase inhibitor therapy is an established standard of care for patients with NSCLC with EGFR mutations, but a worse prognosis has been observed in patients with specific EGFR exon-20 insertion mutations. Mobocertinib (TAK-788) is a novel tyrosine kinase inhibitor developed to target EGFR e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamel, Josette, Meeder, Natalie, Cuellar, Sandra, Chan, David, Huber, Michael, Pasquinelli, Mary, Hulbert, Alicia, Khaddour, Karam, Feldman, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571787/
https://www.ncbi.nlm.nih.gov/pubmed/34766066
http://dx.doi.org/10.1016/j.jtocrr.2021.100241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571787/
https://www.ncbi.nlm.nih.gov/pubmed/34766066
http://dx.doi.org/10.1016/j.jtocrr.2021.100241

Ejemplares similares